米诺西迪尔中毒:一种具有显著心电图变化的耐火冲击病例
Snehangsh Dash1, V K Sashindran1
1Department of Medicine, Air Force Hospital, Gorakhpur, Uttar Pradesh, India.
概括
胺基中毒可能会导致严重的,耐火性休克和明显的心电图 (ECG) 变化. 及时识别和管理对于米诺克西德过量患者的生存至关重要.
科学领域:
- 关键护理医学 关键护理医学
- 临床毒理学 临床毒理学
- 心脏病学 心脏病学
背景情况:
- 米诺西迪尔是一种强大的血管扩张剂,主要用于高血压和脱发.
- 过量服用米诺西迪尔是罕见的,但可能导致危及生命的心血管并发症.
- 耐火性休克和显著的心电图异常在米诺克西迪尔中毒中并不常见.
研究的目的:
- 报告一种罕见的米诺克西迪尔中毒病例.
- 为了突出米诺克西德过量服用,耐火性休克和特定的心电图变化之间的关联.
- 强调早期诊断和敏的管理在米诺克西迪尔毒性的重要性.
主要方法:
- 一份病例报告,详细介绍了一个有意摄入米诺克西迪尔的患者.
- 描述了临床表现,实验室发现和管理策略.
- 电心电图 (ECG) 的发现与临床过程相关分析.
主要成果:
- 患者出现了严重的低血压和耐火性休克,尽管有液体复苏和血管压缩剂.
- 观察到显著的心电图变化,包括ST段升高和T波逆转.
- 通过支持性护理和特定干预措施,患者的病情得到改善.
结论:
- 米诺西德中毒可能会导致严重的血液动力学不稳定性和心脏损害.
- 显著的心电图变化可以作为明氧化毒性的指标.
- 积极的支持性护理对于管理氧化过量时的耐火性休克至关重要.
相关概念视频
Cardiopulmonary Resuscitation IV: Pharmacological Management
17
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
17
Heart Failure Drugs: Inotropic Agents
617
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
617
Acute Coronary Syndrome IV: Interprofessional Care
11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
20
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
20
Acute Coronary Syndrome I: Introduction
30
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
30
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K


